Management

EMIL BILLBÄCK

CHIEF EXECUTIVE OFFICER

Born: 1970
Employed since: 2018
Education: B.Sc. in Business Administration from Karlstad University
Experience: Emil Billbäck joined BONESUPPORT as Chief Executive Officer in March 2018. He has more than 25 years of experience in Life Science, most recently as Chief Commercial Officer at BSN Medical. He has had operational roles at Astra Zeneca and Beiersdorf, and that of Senior Strategic Advisor within ESSITY. Today he is a Board Member of Doctrin and has previously been a Board Member of ATOS. Emil Billbäck has lived and worked in the United States and in Germany.

Shareholding at March 31 2024: 599,098 shares (own holding).

HÅKAN JOHANSSON

CHIEF FINANCIAL OFFICER

Born: 1963
Employed since: 2018
Education: B.Sc. in Business Administration & Finance from Mid Sweden University.
Experience: Håkan Johansson joined BONESUPPORT as Chief Financial Officer in November 2018. He has more than 25 years of experience as CFO and other senior management roles from several industries in the public and private sectors. Prior to BONESUPPORT, Håkan Johansson was CFO for Northern Europe at Thunstall Healthcare Group (2012-2018), a global company in security technology and system solutions for healthcare. He has previously worked at toy manufacturer BRIO AB (publ) and Arctic Paper Group.

Shareholding at March 31 2024: 96,519 shares (own holding).

MICHAEL DIEFENBECK

EVP MEDICAL & CLINICAL AFFAIRS CHIEF MEDICAL OFFICER

Born: 1974
Employed since: 2017
Education: M.D. from Ludwig-Maximilians-University Munich, Germany. Ph.D. from Friedrich-Schiller-Univer- sity, Jena, Germany. Certified orthopedic and trauma surgeon.
Experience: Dr. Michael Diefenbeck joined BONESUPPORT as Chief Medical Officer in April 2017. He founded Scientific Consulting in Orthopedic Surgery in 2014 and subsequently worked on several projects with BONESUPPORT as an independent medical advisor. He is currently honorary consultant at Nuffield Orthopaedic Centre, Oxford University Hospitals. He has 15 years of clinical experience from various hospitals in Germany, is the author of 24 published research articles in the field and is involved in the surgical education and training programs for students at University Hospital Jena.

Shareholding at March 31 2024: 111,160 shares (own holding). He also has 360,000 employee stock options that can be converted to 72,000 shares.

FERGUS MACLEOD

GM & EVP COMMERCIAL OPERATIONS EUROW

Born: 1970
Employed since: 2019
Education: HND Business & Finance, University of Bedfordshire, Executive Leadership Program, Center for Creative Leadership
Experience: Fergus MacLeod joined BONESUPPORT as General Manager & Executive Vice President Com- mercial Operations EUROW in November 2019. He has more than 20 years’ experience from international sales leadership positions in the orthobiology and medical equipment sectors with companies such as Johnson Matthey, RTI Surgical and Stryker.

Shareholding at March 31 2024: 37,500 shares (own holding).

MIKE ROTH

GM & EVP COMMERCIAL OPERATIONS NORTH AMERICA

Born: 1963
Employed since: 2020
Education: BA degree in international development from Clark University
Experience: Michael Roth started at BONESUPPORT as General Manager and Executive Vice President Commercial Operations for North America in June 2020. Michael Roth has over 25 years of experience with senior positions in both large and small companies active in orthopedics, with both direct and distributor-led sales. His most recent role was as Vice President of Sales and Marketing for Surgical Planning Associates (HipXpert). He has also served as Vice President of Sales for the Eastern Region at both Wright Medical and Microport Orthopaedics.

Shareholding at March 31 2024: 54,048 shares (own holding).

HELENA BRANDT

EVP HUMAN RESOURCES

Born: 1965
Employed since: 2017
Education: M.Sc. in International Business & Economics from Lund University. Has studied at University of Cologne, Germany, and at the universities in Cincinnati and Delaware, USA.
Experience: Helena started at BONESUPPORT as Head of Human Resources in October 2017. She is a senior HR leader with more than 20 years of experience in a wide range of industries, from Life Science to IT/Telecom. She has held global HR roles at Astra Zeneca, Sony and Tetra Pak, developing organizations, people, leaders, teams and cultures as well as driving transformation and change.

Shareholding at March 31 2024: 30,976 shares (own holding).

Annelie Aava Vikner

EVP GLOBAL MARKETING

Born: 1971
Employed since: 2019
Education: Bachelor degree in Chemistry from the Linköping Institute of Technology, LIU (Linköping University) and a post graduate certificate in Leadership from Glasgow Caledonian University.
Experience: Annelie Aava Vikner joined BONESUPPORT as Executive Vice President Global Marketing in March 2019. Annelie Aava Vikner has close to 30 years’ of experience from marketing, sales and clinical trials in the field of medical technology & pharma. Before joining BONESUPPORT she worked at Medtronic in different regional leading positions, mainly within marketing.

Shareholding at March 31 2024: 14,480 shares (own holding).

MICHAEL WRANG MORTENSEN

EVP R&D AND OPERATIONS

Born: 1975
Employed since: 2021
Education: M.Sc. in Engineering from Technical University of Denmark, a Ph.D. in Chemistry from University of Copenhagen and an executive MBA from the AVT Business School in Denmark
Experience: Michael Wrang Mortensen joined BONESUPPORT in December 2021 as Executive Vice President with the overall responsibility for R&D and Operations. Michael has more than 15 years of experience from the Medical Device and Healthcare industry with solid leadership and management experience within Innovation, Product Realization, Commercial Development and Operations. Prior to joining BONESUPPORT, Michael Wrang Mortensen was Director for Development and Supply at Nanovi A/S. Before this Michael held various management positions at Ferrosan Medical Devices A/S innovating and developing combination products in partnership with large global players such as Ethicon Biosurgery Inc, Johnson and Johnson.

Shareholding at March 31 2024: 38,835 shares (own holding).